India, Nov. 4 -- Neuronetics, Inc. (STIM), a medical technology company focused on interventional mental health, on Wednesday reported a narrower third-quarter net loss as revenue increased, supported by growth in its Greenbrook clinics business.
The company provides non-invasive transcranial magnetic stimulation (TMS) therapy through its NeuroStar technology and operates interventional psychiatry clinics under the Greenbrook brand. Its treatments are primarily focused on major depressive disorder (MDD).
Q3 Financial Results:
For the three months ended September 30, 2026, net loss attributable to stockholders narrowed to $1.7 million, or $0.02 per share, from $9.0 million, or $0.13 per share, in the prior-year quarter.
Total revenue inc...